Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is not a clinical trial. The aim of this study is to understand the mechanism of action of two recently licensed drugs for ADHD on brain function. We will compare the brain activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by placebo in 20 drug-free patients with ADHD using functional Magnetic Resonance Imaging (fMRI). For this purpose we intend to scan participants during their performance of tasks of attention, working memory, and inhibition, which we know from previous studies to elicit abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

NCT01709695

ADHD Attention Deficit Hyperactivity Disorder

COMPLETED PHASE4

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517

Attention Deficit Hyperactivity Disorder

TERMINATED NA

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523

Attention Deficit Disorder With Hyperactivity

COMPLETED PHASE4

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

NCT00763971

ADHD

COMPLETED PHASE3

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

NCT01415440

Attention Deficit Hyperactivity Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Twenty ADHD patients between 8 and 20 years of age will participate in the double-blind, randomised, active drug condition, within-group, placebo-controlled experimental fMRI study. Each participant will be assessed in baseline measures during a pre-assessment visit. Then the patient will be scanned 3 times under each of these 3 drug conditions: GXR, LISDEX, and placebo. Every patient will receive a single typical clinical weight-adjusted dose of GXR (0.05mg/kg rounded down to the closest dose of 1mg, 2mg, or a maximum of 3mg), LISDEX (for participants aged 8-9 years 20mg regardless of weight; for participants aged 10-20 years the dose will be calculated at 0.5mg/kg rounded to the closest 30, 40, or 50mg, middle doses, e.g. 35mg, will be rounded down) and placebo (10mg Vit C) in one of the scans, in a randomised order. Patients will perform a battery of cognitive tests 3.5 hours after drug administration, after which the will undergo an fMRI scan. The scan will start 4.5 hours after drug administration where drugs have shown to have maximum plasma concentration. Participants will be scanned 3 times, one week apart, under each drug condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Each participant will complete all three experimental conditions (LISDEX, GXR, placebo) in a randomised order.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lisdexamfetamine - Placebo

Group Type ACTIVE_COMPARATOR

Lisdexamfetamine dimesylate

Intervention Type DRUG

Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

Placebo

Intervention Type DRUG

Vitamin C (10mg) tablet

Guanfacine - Placebo

Group Type ACTIVE_COMPARATOR

Guanfacine Extended Release Oral Tablet

Intervention Type DRUG

Guanfacine Extended Release (0.05mg/kg) tablet

Placebo

Intervention Type DRUG

Vitamin C (10mg) tablet

Lisdexamfetamine - Guanfacine

Group Type EXPERIMENTAL

Lisdexamfetamine dimesylate

Intervention Type DRUG

Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

Guanfacine Extended Release Oral Tablet

Intervention Type DRUG

Guanfacine Extended Release (0.05mg/kg) tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lisdexamfetamine dimesylate

Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet

Intervention Type DRUG

Guanfacine Extended Release Oral Tablet

Guanfacine Extended Release (0.05mg/kg) tablet

Intervention Type DRUG

Placebo

Vitamin C (10mg) tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vyvanse (Shire Pharmaceuticals Ltd.) Intuniv (Shire Pharmaceuticals Ltd.)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age range: 8-20 years
* Medication-naïve or non-medicated for two weeks or on stimulant medication, and willing to take the medication off for 48 hours before scans.
* Meeting DSM-5 diagnosis of ADHD
* Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)
* Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating Scales, CPRS (Conners et al., 2008)
* Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)
* IQ \> 70 as tested on the WASI-II (Wechsler et al., 1999)
* Mood and depression symptoms will be allowed as long as they are not the primary diagnosis.

Exclusion Criteria

* IQ \< 70 (Wechsler et al., 1999).
* Comorbidity with schizophrenia, bipolar disorder, learning disability, OCD, severe depression with current suicidal behaviour (as assessed by a clinical interview)
* Neurological problems, i.e. a history of severe neurological illness, e.g. brain tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc.
* Substance abuse history
* Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data integrity or safety of the subject (i.e. contraindicated to any of the treatments) as determined by the investigators
* Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker, implanted medication pumps, neural stimulators, claustrophobia
* Unable to give informed assent or consent in the case of the parent
* Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated states, hyperexcitability, hyperthyroidism, moderate or severe hypertension, symptomatic cardiovascular disease)

Minimum Eligible Age

8 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes